MZMenghua Zhou

Menghua Zhou

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Menghua Zhou has a total of 56 co-authors. Here are the top co-authors by number of shared publications:

  • Yong Ma

    Department of Minimally Invasive Hepatic Surgery The First Affiliated Hospital of Harbin Medical University Harbin China

    4 shared publications
  • Chaoqun Wang

    Department of Hepatobiliary Surgery The Second Affiliated Hospital of Army Medical University Chongqing China

    3 shared publications
  • Dongwang Yan

    Department of General Surgery, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, shanghai, China

    3 shared publications
  • Shounan Lu

    Key Laboratory of Hepatosplenic Surgery, Ministry of Education, Department of Minimally Invasive Hepatic Surgery The First Affiliated Hospital of Harbin Medical University Harbin China

    3 shared publications
  • Bing Yin

    Key Laboratory of Hepatosplenic Surgery, Ministry of Education, Department of Minimally Invasive Hepatic Surgery The First Affiliated Hospital of Harbin Medical University Harbin China

    2 shared publications
  • Bowen Xie

    Department of General Surgery, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, shanghai, China

    2 shared publications

Latest Publications

  • USP21 drives immune evasion in colorectal cancer via deubiquitination and stabilization of β-catenin

    by Mantang Zhou, Anqi Han, Bingjie Guan, Menghua Zhou, Changsong Zheng, Jianjun Xiang, Yushuai Mi, Bowen Xie, Peng Lian, Sanjun Cai, et al.

    The efficacy of immune checkpoint blockade (ICB) therapy in colorectal cancer (CRC) remains limited. Thus, elucidating the molecular mechanisms underlying tumor immune evasion and identifying novel predictive biomarkers are critical for improving immunotherapy outcomes in CRC patients. Here, we report that ubiquitin-specific peptidase 21 (USP21) is overexpressed in tumor tissues from CRC patients who fail to respond to immunotherapy and that its expression is correlated with CD8+ T-cell exclusion and impaired antitumor immunity. To functionally validate these clinical observations, we employed syngeneic mouse models of both microsatellite instability-high (MSI-H) and microsatellite stable (MSS) CRC. Genetic ablation of Usp21 or treatment with the USP21 inhibitor BAY-805 significantly enhanced tumor-reactive CD8+ T-cell responses, suppressed tumor progression, and synergized with anti-PD-1 therapy. Mechanistically, USP21 stabilized β-catenin by removing K48-linked ubiquitin chains, enabling its nuclear translocation and binding to the ATF3 promoter to upregulate ATF3 expression. ATF3 subsequently mediated transcriptional repression of the chemokine CCL4, thereby limiting CD8⁺ T-cell trafficking and function via the CCL4-CCR5 axis. Importantly, the therapeutic potential of targeting USP21 to enhance anti-PD-1 efficacy was further validated in huCD34+ humanized mice. Collectively, our findings identify USP21 as a pivotal regulator of immune evasion, and inhibiting USP21 represents a promising adjuvant strategy to increase the efficacy of ICB in CRC.


  • Top Cited Papers
    Open Access

    Extensive study on the associations of 12 composite inflammatory indices with colorectal cancer risk and mortality: a cross-sectional analysis of NHANES 2001–2020

    by Menghua Zhou, Qi Gu, Mantang Zhou, Songhai Yang, Yuhai Liu, Bingjie Guan, Bowen Xie, Anqi Han, Jianjun Xiang, Dongwang Yan

    Background: Colorectal cancer (CRC) is a leading cause of cancer-related mortality worldwide, with inflammation emerging as a critical factor in its development. We conducted the most comprehensive analysis to date of various inflammatory indices, investigating the associations between these indices and both the risk and mortality of CRC, utilizing nationwide data from the National Health and Nutrition Examination Survey (NHANES). Methods: Data were sourced from NHANES cycles spanning 2001 to 2020. After applying strict inclusion and exclusion criteria, 18 470 eligible samples were analyzed. Twelve composite inflammatory indices were calculated based on peripheral blood cell counts. After adjusting for confounders, we employed logistic regression models to investigate the association between inflammatory indices and CRC risk, supplemented by forest plots, generalized additive model (GAM), and receiver operating characteristic (ROC) curves for a comprehensive understanding. To assess the association between these indices and CRC mortality, we utilized Cox proportional hazards regression analysis, augmented by restricted cubic splines for flexibility, survival curves for visual representation, and ROC curves for discriminative ability. Results: Elevated neutrophil-to-lymphocyte ratio (NLR) and reduced lymphocyte-to-monocyte ratio (LMR) were significantly associated with increased CRC risk (NLR: Q4 vs. Q1: OR = 2.137, 95% CI = 1.212–3.765, P -trend = 0.045; LMR: Q4 vs. Q1: OR = 0.503, 95% CI = 0.274–0.923, P -trend = 0.027). In terms of mortality risk, low LMR, high neutrophil-to-platelet ratio (NPR), and high systemic immune-inflammation index (SII) showed associations with adverse outcomes. Higher SII ( P = 0.0459), NPR ( P = 0.0333) levels trended toward poorer prognosis, while higher LMR levels predicted better prognosis ( P = 0.0056). The association between these indicators and the risk and prognosis of CRC tends to be more of a nonlinear correlation. In terms of their performance in assessing the risk and prognosis of CRC, there is no significant difference between single indicators and combined indicators. Conclusions: Elevated NLR and reduced LMR may serve as non-invasive biomarkers for early detection and risk stratification of CRC. Low LMR, high NPR, and high SII are linked to adverse mortality outcomes. Dynamic monitoring based on these indices has the potential to offer new insights and directions for the diagnosis and treatment of CRC.


  • Open Access

    IRG1 restrains M2 macrophage polarization and suppresses intrahepatic cholangiocarcinoma progression via the CCL18/STAT3 pathway

    by Menghua Zhou, Hongjun Yu, Miaoyu Bai, Shounan Lu, Chaoqun Wang, Shanjia Ke, Jingjing Huang, Zihao Li, Yanan Xu, Bing Yin, et al.

    Intrahepatic cholangiocarcinoma (ICC) is a highly malignant and aggressive cancer whose incidence and mortality continue to increase, whereas its prognosis remains dismal. Tumor‐associated macrophages (TAMs) promote malignant progression and immune microenvironment remodeling through direct contact and secreted mediators. Targeting TAMs has emerged as a promising strategy for ICC treatment. Here, we revealed the potential regulatory function of immune responsive gene 1 (IRG1) in macrophage polarization. We found that IRG1 expression remained at a low level in M2 macrophages. IRG1 overexpression can restrain macrophages from polarizing to the M2 type, which results in inhibition of the proliferation, invasion, and migration of ICC, whereas IRG1 knockdown exerts the opposite effects. Mechanistically, IRG1 inhibited the tumor‐promoting chemokine CCL18 and thus suppressed ICC progression by regulating STAT3 phosphorylation. The intervention of IRG1 expression in TAMs may serve as a potential therapeutic target for delaying ICC progression.


  • Open Access

    Surgical smoke: A hidden killer in the operating room

    by Yong-Zhi Zhou, Chao-Qun Wang, Meng-Hua Zhou, Zhong-Yu Li, Dong Chen, Ai-Ling Lian, Yong Ma


  • Open Access

    Tumor-associated macrophages in cholangiocarcinoma: complex interplay and potential therapeutic target

    by Menghua Zhou, Chaoqun Wang, Shounan Lu, Yanan Xu, Zihao Li, Hongchi Jiang, Yong Ma


  • Open Access

    NNMT Promotes Aerobic Glycolysis and Tumorigenesis by Upregulating EGFR Expression in Cholangiocarcinoma

    by Shounan Lu, Shanjia Ke, Chaoqun Wang, Yanan Xu, Zihao Li, Keda Song, Miaoyu Bai, Menghua Zhou, Hongjun Yu, Bing Yin, et al.

    Background: Current treatments for cholangiocarcinoma (CCA) remain ineffective because our knowledge of CCA carcinogenesis is limited. Nicotinamide N-methyltransferase (NNMT), a member of the N-methyltransferase family, plays an important role in tumorigenesis. However, its expression and biological functions in CCA remain to be established. The aim of this study was to define the functions and underlying mechanisms of NNMT in the progression of CCA. Methods: High NNMT expression in CCA tissues was identified using western blotting and immunohistochemistry (IHC). Cell proliferation, migration and invasion assays were performed to confirm the phenotype associated with NNMT expression. Xenograft tumor models were applied in the in vivo study. High-performance liquid chromatography (HPLC) and chromatin immunoprecipitation (ChIP) assays were applied to confirm the association of NNMT and methylated histones at the promoter region of epidermal growth factor receptor (EGFR). Results: We identified a significantly higher NNMT expression level in human CCA tissues than that in adjacent normal tissues. Increased NNMT expression promoted CCA cell proliferation and metastasis in vitro and in vivo. Mechanistically, NNMT inhibited the level of histone methylation in CCA cells by consuming the methyl donor SAM, thereby promoting the expression of EGFR. EGFR may activate the aerobic glycolysis pathway in CCA cells by activating the STAT3 signaling pathway. Conclusions: In our study, we identified NNMT as an oncogene in CCA and provided mechanistic insights into the roles of NNMT in CCA progression. Funding Information: This study was supported by the National Natural Science Foundation of China (81100305, 81470876, 81502605 and 81270527). Declaration of Interests: The authors declare that they have no competing interests. Ethics Approval Statement: Ethical approval was acquired from the Research Ethics Committee of the First Affiliated Hospital of Harbin Medical University, and each patient provided informed consent.